Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma

NCT ID: NCT01948180

Last Updated: 2019-03-13

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-09-30
• Study Completion Date: 2018-09-07

Brief Summary

To investigate the efficacy of autologous EBV-specific T-cells for the treatment of patients with aggressive EBV positive extranodal NK/T-cell lymphoma

Conditions

Lymphoma, Extranodal NK-T-Cell; EBV

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

baltaleucel-T

Treatment consists of 2 infusions of 2x10E7 cells/m2 given on Days 1 and 15 intravenously via a peripheral or central line over a 1 to 10 minute period.

Subjects who tolerate the study treatment well and who do not require treatment with an alternative chemotherapeutic agent will be eligible for up to 3 additional infusions of 2x10E7 cells/m2 administered at week 8, month 3 and month 6.

Group Type: EXPERIMENTAL

baltaleucel-T

Intervention Type: BIOLOGICAL

Autologous EBV-specific T-cells

Interventions

baltaleucel-T

Autologous EBV-specific T-cells

Intervention Type: BIOLOGICAL

Other Intervention Names

CMD-003

Eligibility Criteria

Inclusion Criteria

1. Diagnosis of extranodal NK/T lymphoma, per WHO classification, 4th ed., which must include EBV tumor positivity, measured either by EBV encoded RNA (EBER) or LMP1 immunostaining.

2. a) Active Disease

(1) Clinically suspected or documented relapse/progression, in first or second relapse following at least one cycle of an asparaginase-based chemotherapy regimen OR (2) Initial disease or first or second relapse and unable to tolerate one full cycle of asparaginase-based chemotherapy regimen OR b) High-risk disease (stage III/IV, KPI groups 3-4 or IPI intermediate-high) prior to second CR regardless of previous chemotherapy.

3. Male or female ≥ 18 years of age. 4. Weigh ≥ 35 kg. 5. ECOG performance score 0-2, inclusively. 6. Negative β-hCG test in women of childbearing potential. 7. Able to understand and comply with the requirements of the study and to provide written informed consent.

1. Documented relapse or progression following at least one prior cycle of an asparaginase-containing chemotherapy regimen.

2. Active disease based on any one of the following present at the baseline study visit or within two weeks prior to the baseline study visit:

1. Imaging (may use local imaging)

2. Clinical sign(s) including skin lesions consistent with lymphoma, organ dysfunction or organomegaly not attributable to other causes; or other clinical sign(s)

3. Detectable blood or plasma ENV DNA (may use local laboratory)

3. Completed most recent course of chemotherapy at least 2 weeks prior to first study drug dose.

4. Recovery from acute hematological, hepatic and renal chemotherapy-related toxicities as defined by ≤ Grade 1 according to NCI CTCAE v4.0.

5. Life expectancy ≥ 8 weeks.

Exclusion Criteria

1. CNS lymphoma.

2. NK cell leukemia.

3. Hemophagocytic lymphohistiocytosis.

4. Positive for HIV, hepatitis B, hepatitis C, syphilis or human T Cell leukemia virus (HTLV).

5. Use of systemic corticosteroids >0.5 mg/kg/day within 10 days prior to obtaining 200 mL whole blood starting material.

6. Patient is pregnant or lactating.

7. Active second malignancy.

8. Any prior allogeneic hematopoietic stem cell or solid organ transplant.

9. Asparaginase refractory disease, defined by any one of the following:

1. Progression at any time during initial asparaginase based chemotherapy and up to 3 months after end of initial asparaginase based chemotherapy, OR

2. Failure to achieve at least PR with initial asparaginase based chemotherapy.

10. Absolute lymphocyte count (ALC) <400/µL.

11. Any previous autologous EBV specific T cell treatment.

12. Systemic fungal, bacterial, viral or other infection that is not controlled.

13. Third or greater relapse.

FOR TREATMENT PHASE:

1. Use of any investigational agents within prior 4 weeks.

2. Radiotherapy within prior 3 weeks.

3. Major surgery within prior 2 weeks.

4. Systemic corticosteroids within 24 hours prior to study drug administration.

5. Evidence of hepatic dysfunction based on serum total bilirubin >3 times upper limit of normal (ULN), or ALT >5 times ULN or AST >5 times ULN.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cell Medica Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Helen Heslop, MD

Role: PRINCIPAL_INVESTIGATOR

Baylor College of Medicine

Kurt Gunter, MD

Role: STUDY_DIRECTOR

Cell Medica

Locations

Dana-Farber Cancer Center

Boston, Massachusetts, United States

Mayo Clinic

Rochester, Minnesota, United States

The Ohio State University Comprehensive Cancer Center

Columbus, Ohio, United States

Baylor College of Medicine

Houston, Texas, United States

MD Anderson Cancer Center

Houston, Texas, United States

Universitaire Ouest

Paris, , France

Centre Hospitalier de Lyon

Pierre-Bénite, , France

Samsung Medical Center

Seoul, , South Korea

Asan Cancer Center

Seoul, , South Korea

University College London Hospital

London, UK, United Kingdom

The Christie Clinic

Manchester, UK, United Kingdom

Countries

United States; France; South Korea; United Kingdom

Other Identifiers

CM-2013-01

Identifier Type: -

Identifier Source: org_study_id